Peter Donaldson, Derek Doherty, James Underhill, Roger Williams – 1 July 1994 – The dual observations that human leukocyte antigens have an antigen‐binding groove and that the polymorphism we study as human leukocyte antigen types is largely related to amino acid substitutions in and around that groove have provided a new focus for immunogenetic studies.
Andres T. Blei – 1 July 1994
The French METAVIR Cooperative Study Group, P. Bedossa – 1 July 1994 – Liver biopsy is used as the “gold standard” for the assessment of the stage and degree of activity in chronic hepatitis C and is of major importance in evaluating the effects of treatment. Because numerous therapeutic trials are undertaken with histological control, the reproducibility of liver biopsy interpretation appears essential.
Lars Lööf, Hans‐Olov Adami, Pär Sparén, Åke Danielsson, Ljusk Siw Eriksson, Rolf Hultcrantz, Stefan Lindgren, Rolf Olsson, Hanne Prytz, Bengt‐Olof Ryden, Hanna Sandberg‐Gertzen, Sven Wallerstedt – 1 July 1994 – A cohort of 559 patients in Sweden who satisfied predetermined criteria for the diagnosis of primary biliary cirrhosis was followed with respect to the incidence of cancer during the period of 1958 to 1988. The mean follow‐up time from the time of primary biliary cirrhosis diagnosis was 9.0 ± 54 yr.
Bruno Stieger, Peter J. Meier, Lukas Landmann – 1 July 1994 – We investigated the effect of bile duct ligation and its release on membrane traffic and plasma membrane protein distribution in rat hepatocytes. Immunofluorescence studies with monoclonal antibodies against six domain‐specific surface antigens revealed that bile duct ligation leads to an accumulation of pericanalicular vesicles containing canalicular antigens.
Jonathan, Harrison, Paul McMaster – 1 July 1994
Jean‐Bernard Otte, Jean De Ville De Goyet, Raymond Reding, Victoria Hausleithner, Etienne Sokal, Christophe Chardot, Benoit Debande – 1 July 1994 – Biliary atresia is the most frequent cause of chronic cholestasis in infants. When left untreated, this condition leads to death from liver insufficiency within the first 2 yr of life. The modern therapeutic approach consists of a sequential strategy with Kasai portoenterostomy as a first step and, in case of failure, liver transplantation. After portoenterostomy, no more than 20% to 30% of patients will live jaundice‐free into adulthood.
Edward Gane, Bernard Portmann, Romil Saxena, Philip Wong, John Ramage, Roger Williams – 1 July 1994 – Nodular regenerative hyperplasia has not previously been reported in patients who have undergone orthotopic liver transplantation. In this report we describe the clinical, biochemical and histologic findings in nine liver transplant recipients in whom nodular regenerative hyperplasia developed between 6 and 144 mo (median, 64 mo) after transplantation.
Arieh Bomzon, Wladimiro Jiménez – 1 July 1994